SIL204

SIL204 is a second-generation small interfering RNA (siRNA) therapeutic designed to silence mutant KRAS oncogenes—specifically targeting a broad spectrum of mutations including G12D, G12V, G12R, Q61H, and G13D. Developed by Silexion Therapeutics (formerly Silenseed), it employs an optimized lipid-conjugated and microparticle extended-release delivery system to enhance tumor cell penetration and prolong drug release. The primary mechanism is RNA interference-mediated inhibition of KRAS protein expression at the mRNA level. Preclinical studies have demonstrated potent anti-tumor activity in pancreatic cancer models (including orthotopic models mimicking human disease), as well as efficacy in colorectal and non-small cell lung cancer cell lines harboring relevant KRAS mutations. The drug is being developed for both intratumoral (via EUS endoscopy) and systemic administration routes to address both primary tumors and metastases[1][2][3][4][5][6][7][8].

Other names

SIL 204SIL204SIL-204